Mar 01, 2018 7:30am EST Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
Feb 27, 2018 7:30am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results
Feb 16, 2018 5:15pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Jan 26, 2018 4:05pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Jan 05, 2018 4:05pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Jan 04, 2018 7:30am EST Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
Dec 08, 2017 7:05pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Dec 08, 2017 7:30am EST Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
Nov 17, 2017 4:05pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
